BUILDING A STRUCTURED MONITORING AND EVALUATING SYSTEM OF POSTMARKETING DRUG USE IN SHANGHAI

Main Article Content

Wenmin Du
Mitchell Levine
Longxing Wang
Chengdong Yi
Hongmin Wang
Xiaoyu Wang
Hongjuan Xie Xie
Jianglong Xu
Huilin Jin
Tongchun Wang
Gang Huang
Ye Wu

Keywords

Post-marketing, record linkage, Shanghai

Abstract

In order to understand a drug’s full profile in the post-marketing environment, information is needed regarding  utilization  patterns,  beneficial  effects,  ADRs  and  economic  value.  China,  the  most populated country in the world, has the largest number of people who are taking medications. To begin to appreciate the impact of these medications, a multifunctional evaluation and surveillance system was developed, the Shanghai Drug Monitoring and Evaluative System (SDMES). Set up by the Shanghai Center for Adverse Drug Reaction Monitoring in 2001, the SDMES contains three databases: a population health data base of middle aged and elderly persons; hospital patient medical records; and a spontaneous ADR reporting database. Each person has a unique identification and Medicare number, which permits record-linkage within and between these three databases. After more than three years in development, the population health database has comprehensive data for more than 320,000 residents. The hospital database has two years of inpatient medical records from five major hospitals, and will be increasing to 10 hospitals in 2007. The spontaneous reporting ADR database has collected   20,205   cases   since   2001   from   approximately   295   sources,   including   hospitals, pharmaceutical  companies,  drug  wholesalers  and  pharmacies.  The  SDMES  has  the  potential  to become an important national and international pharmacoepidemiology resource for drug evaluation.

Abstract 101 | PDF Downloads 66

References

1. Brian L. Strom. Preface. Pharmacoepidemiology (4th edition, Edited by Brian L. Strom):xv-xvii.
2. Drazen JM. COX-2 inhibitors -- a lesson in unexpected problems. N Engl J Med 2005;352:1131-1132.
3. Psaty BM, Furberg CD. COX-2 inhibitors -- lessons in drug safety. N Engl J Med 2005;352:1133-1135.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr 20;
354(16):1706-17.
5. Ahmad SR, Goetsch RA, Marks NS. Spontaneous Reporting in the United States. Pharmacoepidemiology (4th edition, Edited by Brian L. Strom):135-159.
6. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005 Apr;21(4):565-70.
7. Segal ES, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005;28(11):971-80.
8. Brian L. Strom. Overview of Automated Databases n pharmacoepidemiology.Pharmacoepidemiology (4th edition, Edited by Brian L. Strom):219-222.
9. Brian L. Strom. What is pharmacoepidemiology?ibid:3-15.
10. Ralph Edwards, Sten Olsson, Marie Lindquist, Bruce Hugman. Global drug surveillance: the WHO programme for international drug monitoring. ibid:161-183.
11. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999 Mar 3;281(9):824-9.
12. Boyd IW. The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. Toxicology 2002 Dec 27;181-182:99-102.
13. Crombie I. Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions. Hum Toxicol 1984 Aug;3(4):261-9.
14. Liu BA, Knowles SR, Mittmann N, Einarson T, Shear NH. Reporting of fatal adverse drug reactions. Can J Clin Pharmacol Summer;8(2):84-8.
15. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998 Jul 11;317(7151):119-20.
16. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA 2004 Dec 1;292(21):2643-6.
17. Shakir SAW. Prescription-Event Monitoring. Pharmacoepidemiology (4th edition, Edited by Brian L. Strom):203-216.
18. Gelfand JM, Margolis DJ, Dattani H. The UK General Practice Research Database. ibid:337-346.
19. Ssunders KW, Davis RL, Stergachis A. Group Health Cooperative. ibid:223-240.
20. Selby JV, Smith DH, Johnson ES, Raebel MA, Friedman GD, McFarland BH. Kaiser Permanente Medical Care Program. ibid:241-260.
21. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. ibid:261-270.
22. Shatin D, Rawson NSB, Stergachis A. United Health Group. ibid:271-280.
23. Hennessy S, Carson JL, Ray WA, Strom BL. Medicaid Databases. ibid:281-294.
24. Downey W, Stang MR, Beck P, Osei W, Nichol JL. Health Services Databases in Saskatchewan. ibid:295-310.
25. Leufkens HG, Urquhart J. Automated Pharmacy Record Linkage in The Netherlands. ibid:311-322.
26. Tang WL, Wang YM, Du WM, Cheng NN, Chen BY. Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community. Pharmacoepidemiol Drug Saf 2006 Feb;15(2):123-30.
27. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006 May;26(5):601-8.